Pac Premier
Giving Guide
You are here:  Home  >  Biotech  >  Current Article

Amgen’s Repatha drug approved in China

By   /   Thursday, January 24th, 2019  /   Comments Off on Amgen’s Repatha drug approved in China

    Print       Email
Thousand Oaks biotech giant Amgen announced a new approval in China on Jan. 24 for its cardiovascular drug Repatha as well as positive new data for its rheumatoid arthritis biosimilar ABP 798. The National Medical Products Administration approval of Repatha makes it the first PCSK9 inhibitor approved in China for use in adults with atherosclerotic…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email